SCU-CT Plant Stemcell Bioengineering Partnership: A Huge step in a right direction
With reference to the news release by British-American Tobacco on 01 April 2020 titled “BAT working on potential COVID-19 vaccine through US bio-tech subsidiary”.
The excerpt of the article is “BAT’s US bio-tech subsidiary, Kentucky BioProcessing (“KBP”), is developing a potential vaccine for COVID-19 and is now in pre-clinical testing. If testing goes well, BAT is hopeful that, with the right partners and support from government agencies, between 1 and 3 million doses of the vaccine could be manufactured per week, beginning in June.”
With this positive development in United States, Stem Cell United (“SCU”) is well-poised to capitalize on the potential opportunity in China by harnessing its proprietary technology in molecular farming as well as its plant stem cell bioengineering partnership with China Tobacco (“CT”) on developing alternative applications for its tobacco plants.
Already in the research and development stage of unlocking the potential of Tobacco as transgenic plant to produce biomaterial cannabinoids (CBx) in our joint cultivation site at Kunming, SCU is confident that it is able to replicate the same success in plant-based vaccine development.
This also commensurate with our partner, China Tobacco’s mandate in diversifying the uses of the tobacco plants.
In line with our corporate philosophy of empower and enriching the society amid the covid-19 crisis, SCU will strive to deliver a strong sustainable plant-based solution as part of the global effort to stem this pandemic.